Multicenter Evaluation of Independent High-Throughput and RT-qPCR Technologies for the Development of Analytical Workflows for Circulating MiRNA Analysis

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 May 9

PMID 32380788

Citations 6

Authors

Anna Babayan

Martin H D Neumann

Andrei Herdean

Jonathan M Shaffer

Melanie Janning

Franca Kobus

Sonja Loges

Francesca Di Pasquale

Mikael Kubista

Martin Schlumpberger

Rita Lampignano

Thomas Krahn

Thomas Schlange

Markus Sprenger-Haussels

Klaus Pantel

Vera Kloten

Affiliations

Soon will be listed here.

Abstract

Background: Among emerging circulating biomarkers, miRNA has the potential to detect lung cancer and follow the course of the disease. However, miRNA analysis deserves further standardization before implementation into clinical trials or practice. Here, we performed international ring experiments to explore (pre)-analytical factors relevant to the outcome of miRNA blood tests in the context of the EU network CANCER-ID.

Methods: Cell-free (cfmiRNA) and extracellular vesicle-derived miRNA (EVmiRNA) were extracted using the miRNeasy Serum/Plasma Advanced, and the ExoRNeasy Maxi kit, respectively, in a plasma cohort of 27 NSCLC patients and 20 healthy individuals. Extracted miRNA was investigated using small RNA sequencing and hybridization platforms. Validation of the identified miRNA candidates was performed using quantitative PCR.

Results: We demonstrate the highest read counts in healthy individuals and NSCLC patients using QIAseq. Moreover, QIAseq showed 15.9% and 162.9% more cfmiRNA and EVmiRNA miRNA counts, respectively, in NSCLC patients compared to healthy control samples. However, a systematic comparison of selected miRNAs revealed little agreement between high-throughput platforms, thus some miRNAs are detected with one technology, but not with the other. Adding to this, 35% (9 of 26) of selected miRNAs in the cfmiRNA and 42% (11 of 26) in the EVmiRNA fraction were differentially expressed by at least one qPCR platform; about half of the miRNAs (54%) were concordant for both platforms.

Conclusions: Changing of (pre)-analytical methods of miRNA analysis has a significant impact on blood test results and is therefore a major confounding factor. In addition, to confirm miRNA biomarker candidates screening studies should be followed by targeted validation using an independent platform or technology.

Citing Articles

Lung cancer cell-derived exosomes: progress on pivotal role and its application in diagnostic and therapeutic potential.

Abdul Manap A, Ngwenya F, Kalai Selvan M, Arni S, Hassan F, Mohd Rudy A Front Oncol. 2024; 14:1459178.

PMID: 39464709 PMC: 11502357. DOI: 10.3389/fonc.2024.1459178.

Analysis of the longitudinal stability of human plasma miRNAs and implications for disease biomarkers.

Sandau U, Wiedrick J, McFarland T, Galasko D, Fanning Z, Quinn J Sci Rep. 2024; 14(1):2148.

PMID: 38272952 PMC: 10810819. DOI: 10.1038/s41598-024-52681-5.

Changes in Multiple microRNA Levels with Antidepressant Treatment Are Associated with Remission and Interact with Key Pathways: A Comprehensive microRNA Analysis.

Funatsuki T, Ogata H, Tahara H, Shimamoto A, Takekita Y, Koshikawa Y Int J Mol Sci. 2023; 24(15).

PMID: 37569574 PMC: 10418406. DOI: 10.3390/ijms241512199.

Research progress of circulating non-coding RNA in diagnosis and treatment of hepatocellular carcinoma.

You J, Xia H, Huang Z, He R, Zhao X, Chen J Front Oncol. 2023; 13:1204715.

PMID: 37546394 PMC: 10400719. DOI: 10.3389/fonc.2023.1204715.

A Cross-Comparison of High-Throughput Platforms for Circulating MicroRNA Quantification, Agreement in Risk Classification, and Biomarker Discovery in Non-Small Cell Lung Cancer.

Gargiuli C, De Cecco L, Mariancini A, Ianno M, Micali A, Mancinelli E Front Oncol. 2022; 12:911613.

PMID: 35928879 PMC: 9343840. DOI: 10.3389/fonc.2022.911613.

References

Bayraktar R, Van Roosbroeck K, Calin G . Cell-to-cell communication: microRNAs as hormones. Mol Oncol. 2017; 11(12):1673-1686. PMC: 5709614. DOI: 10.1002/1878-0261.12144. View

Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, Chen C . Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods. 2014; 11(8):809-15. DOI: 10.1038/nmeth.3014. View

Giraldez M, Spengler R, Etheridge A, Godoy P, Barczak A, Srinivasan S . Comprehensive multi-center assessment of small RNA-seq methods for quantitative miRNA profiling. Nat Biotechnol. 2018; 36(8):746-757. PMC: 6078798. DOI: 10.1038/nbt.4183. View

Androvic P, Romanyuk N, Urdzikova-Machova L, Rohlova E, Kubista M, Valihrach L . Two-tailed RT-qPCR panel for quality control of circulating microRNA studies. Sci Rep. 2019; 9(1):4255. PMC: 6414634. DOI: 10.1038/s41598-019-40513-w. View

Lampignano R, Kloten V, Krahn T, Schlange T . Integrating circulating miRNA analysis in the clinical management of lung cancer: Present or future?. Mol Aspects Med. 2020; 72:100844. DOI: 10.1016/j.mam.2020.100844. View

Neumann M, Bender S, Krahn T, Schlange T . ctDNA and CTCs in Liquid Biopsy - Current Status and Where We Need to Progress. Comput Struct Biotechnol J. 2018; 16:190-195. PMC: 6024152. DOI: 10.1016/j.csbj.2018.05.002. View

Bullock M, Silva A, Kanlikilicer-Unaldi P, Filant J, Rashed M, Sood A . Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer. Noncoding RNA. 2018; 1(1):53-68. PMC: 5932539. DOI: 10.3390/ncrna1010053. View

Li L, Chang H . Physiological roles of long noncoding RNAs: insight from knockout mice. Trends Cell Biol. 2014; 24(10):594-602. PMC: 4177945. DOI: 10.1016/j.tcb.2014.06.003. View

Kloten V, Neumann M, Di Pasquale F, Sprenger-Haussels M, Shaffer J, Schlumpberger M . Multicenter Evaluation of Circulating Plasma MicroRNA Extraction Technologies for the Development of Clinically Feasible Reverse Transcription Quantitative PCR and Next-Generation Sequencing Analytical Work Flows. Clin Chem. 2019; 65(9):1132-1140. DOI: 10.1373/clinchem.2019.303271. View

10.

Androvic P, Valihrach L, Elling J, Sjoback R, Kubista M . Two-tailed RT-qPCR: a novel method for highly accurate miRNA quantification. Nucleic Acids Res. 2017; 45(15):e144. PMC: 5587787. DOI: 10.1093/nar/gkx588. View

11.

Arroyo J, Chevillet J, Kroh E, Ruf I, Pritchard C, Gibson D . Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011; 108(12):5003-8. PMC: 3064324. DOI: 10.1073/pnas.1019055108. View

12.

Lopez J, Diallo A, Cruceanu C, Fiori L, LaBoissiere S, Guillet I . Biomarker discovery: quantification of microRNAs and other small non-coding RNAs using next generation sequencing. BMC Med Genomics. 2015; 8:35. PMC: 4487992. DOI: 10.1186/s12920-015-0109-x. View

13.

Morris K, Mattick J . The rise of regulatory RNA. Nat Rev Genet. 2014; 15(6):423-37. PMC: 4314111. DOI: 10.1038/nrg3722. View

14.

Godoy P, Barczak A, DeHoff P, Srinivasan S, Etheridge A, Galas D . Comparison of Reproducibility, Accuracy, Sensitivity, and Specificity of miRNA Quantification Platforms. Cell Rep. 2019; 29(12):4212-4222.e5. PMC: 7499898. DOI: 10.1016/j.celrep.2019.11.078. View

15.

Chen X, Liang H, Zhang J, Zen K, Zhang C . Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 2012; 22(3):125-32. DOI: 10.1016/j.tcb.2011.12.001. View

16.

Dragomir M, Chen B, Calin G . Exosomal lncRNAs as new players in cell-to-cell communication. Transl Cancer Res. 2018; 7(Suppl 2):S243-S252. PMC: 6107076. DOI: 10.21037/tcr.2017.10.46. View

17.

Babayan A, Pantel K . Advances in liquid biopsy approaches for early detection and monitoring of cancer. Genome Med. 2018; 10(1):21. PMC: 5861602. DOI: 10.1186/s13073-018-0533-6. View

18.

Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee J, Lotvall J . Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6):654-9. DOI: 10.1038/ncb1596. View